Cordis Endovascular's vena cava filter gets FDA go-ahead:
This article was originally published in Clinica
Executive Summary
Cordis Endovascular, a Johnson & Johnson company, has received US FDA 510(k) clearance to market its 6F TRAPEASE permanent vena cava filter. Designed to prevent pulmonary embolism, the 6 French delivery system provides flexibility and support, minimising patient trauma and insertion site thrombosis. It has a symmetrical double-basket design, providing two levels of filtering and is the smallest, least invasive permanent vena cava filter available, claims the Warren, New Jersey-based company.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.